<DOC>
	<DOCNO>NCT00045448</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness combine flavopiridol docetaxel treat patient advance solid tumor .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose flavopiridol administer combination 2 different dos docetaxel patient advance solid tumor . - Determine clinical pharmacokinetics regimen patient . - Determine , preliminarily , therapeutic activity regimen patient . OUTLINE : This dose-escalation study flavopiridol . Patients receive docetaxel IV 30 minute follow least 4 hour later flavopiridol IV 1 hour day 1 , 8 , 15 . Courses repeat every 4 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos flavopiridol maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 6 patient experience dose-limiting toxicity . Separate MTDs flavopiridol determine flavopiridol combine 2 different dos docetaxel . A total 10 patient treat flavopiridol MTD . Patients follow every 3 month 1 year , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : A total 6-56 patient accrue study .</detailed_description>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced solid tumor refractory standard therapy standard therapy exist Measurable evaluable disease No symptomatic untreated CNS metastasis primary CNS neoplasm PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 70100 % Life expectancy Not specify Hematopoietic WBC least 3,500/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 8 g/dL Hepatic Bilirubin great upper limit normal ( ULN ) SGOT/SGPT great 2.5 time ULN alkaline phosphatase great ULN OR Alkaline phosphatase great 2.5 time ULN SGOT/SGPT great ULN Renal Creatinine great 1.5 mg/dL Cardiovascular No history cardiac arrhythmia No congestive heart failure No myocardial infarction within past 6 month Other No concurrent serious uncontrolled infection No diabetes adequately control medication No peripheral neuropathy great grade 1 No know allergy docetaxel medication formulate Polysorbate 80 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 month study PRIOR CONCURRENT THERAPY : Biologic therapy At least 4 week since prior immunotherapy Chemotherapy At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) Prior taxanes allow No prior flavopiridol Endocrine therapy At least 4 week since prior hormonal therapy Radiotherapy At least 4 week since prior radiotherapy Surgery Not specify Other Recovered prior therapy No prior enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>